- ￥5300
- GeneTex
- 美国
- GTX48705
- 2025年07月11日
- WB, ELISA
- Rabbit
- Mouse
企业认证
相关产品推荐更多 >
![GSTO1 antibody [N1C3]](https://img1.dxycdn.com/2023/0516/045/6925717576889828561-14.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a peptide corresponding to an internal portion of mouse c-Myb protein.
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
- 克隆性：
Polyclonal
- 标记物：
Unconjugated
- 适应物种：
Mouse
- 保质期：
12 months from the shipping date of the product.
- 抗原来源：
Mouse
- 目录编号：
GTX48705
- 级别：
Primary Antibodies
- 库存：
Available
- 供应商：
GeneTex
- 宿主：
Rabbit
- 应用范围：
WB, ELISA
- 浓度：
1.51 mg/ml (Please refer to the vial label for the specific concentration.)
- 靶点：
C-Myb
- 抗体英文名：
C-Myb antibody
- 抗体名：
C-Myb 抗体
- 规格：
50 μg
Western blot using GeneTex's affinity purified anti-C-Myb antibody in Cos7 cell lysates: Lane 1: vector; Lane 2: transfected with c-myb, no treatment; Lane 3: transfected with c-Myb and heat stress-treated (incubation at 42oC for 30 minutes) to induce c-Myb modification. Lane 3 shows detection of bands at 75, 98, and 125kDa corresponding to overexpressed c-Myb (arrows): wild-type, with one attached SUMO molecule, and with two attached SUMO molecules, respectively. Nitrocellulose 0.45μm membrane was blocked for 1 hr at RT in 10% BLOTTO in PBS. The primary antibody was used at 1:500.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验The proto-oncogene c-myb is a cellular homolog of a viral oncogene v-myb found in two independently derived avian acute leukemia viruses: avian myeloblastosis vn-us (AMV) and E26 leukemia virus (1 ). The myb gene is highly conserved
c-myb Antisense Oligonucleotide Therapeutics for Hematologic Malignancies
Although improved significantly, conventional treatment of hematologic malignancy remains inadequate for many patients. Novel treatment approaches could be useful if they would be more efficacious and less toxic. One such approach could involve
Generation of Antibody Molecules Through Antibody Engineering
been overcome to a large extent using genetic-engineering techniques to produce chimeric mouse/human and completely human antibodies. Such an approach is particularly suitable because of the domain structure of the antibody molecule ( 2 ), where functional
技术资料暂无技术资料 索取技术资料
